This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Astex Pharmaceuticals Pipeline Data Presentations At AACR

DUBLIN, Calif., April 3, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of thirteen abstracts covering internal and partner funded pipeline product data for poster or oral presentation at the American Association for Cancer Research (AACR) Annual Meeting April 6 to 10, 2013 in Washington, DC.

"AACR will be a foundational meeting for presenting significant data supporting our clinical programs," said James S.J. Manuso, PhD, chairman and chief executive officer. "Additional data presentations are anticipated for future meetings. Preliminary SGI-110 phase 2 data are expected to be presented at ASH."

SGI-110, a novel hypomethylating agent, will be highlighted in six presentations, including an oral mini-symposia presentation on ovarian cancer chemosensitization, as well as poster presentations on its immunomodulatory activity and its activity in lung cancer:
In vivo Immunomodulatory Activity of SGI-110, a Second Generation Hypomethylating Agent, in Hematologic Malignancies
Abstract 680, Sunday Apr 7, 1:00 - 5:00 pm ET, poster presentation
SGI-110 and Entinostat Therapy Reduces Lung Tumor Burden and Reprograms the Epigenome
Abstract 679, Sunday, Apr 7, 1:00 – 5:00 pm ET, poster presentation
The Novel, Small Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Abstract 4623, Tuesday, Apr 9, 4:05 - 4:20 pm ET, oral presentation

AT13387, an HSP90 inhibitor, will be presented in a poster session reporting preclinical data in sensitive and resistant prostate cancer tumor models:
In vitro and In vivo Anti-Tumor Activity of the Next Generation HSP90 Inhibitor, AT13387, in Both Hormone-Sensitive and Castration-Resistant Prostate Cancer Models
Abstract 2433, Tuesday, Apr 9, 8:00 am - 12:00 pm ET, poster presentation

Two of the four partner funded programs in our portfolio will have data supporting ongoing clinical development:
AZD5363, a PKB/Akt inhibitor:
Results of Two Phase I Multicenter Trials of AZD5363, an Inhibitor of AKT1, 2 and 3: Biomarker and Early Clinical Evaluation in Western and Japanese Patients with Advanced Solid Tumors
Abstract LB-66, Sunday, Apr 7, 3:30 - 3:50 pm ET, oral presentation
LEE011, a CDK4/6 inhibitor:
CDK4/CDK6 Inhibition is Potently Active in a Definable Subset of Human Neuroblastomas
Abstract 2744, Tuesday, Apr 9, 8:00 am - 12:00 pm ET, poster presentation

Additional poster references may be found on the AACR 2013 Annual Meeting website, and select posters will be made available for viewing on the company's website following the respective presentations.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs